

*Vienna, Austria*

Annual Congress of the  
European Association of Nuclear Medicine  
October 21 –25, 2017  
Vienna, Austria

## **Pre-Congress Symposium 7 (Oncology/Radionuclide Therapy)** **Saturday, October 21, 13:00-16:00**

### **Session Title**

### **PET Imaging for Response Assessment of Immune Modulation and Therapy**

#### **Chairs**

Nicolas Aide (Caen)

Elisabeth de Vries (Groningen)

#### **Programme**

- 13:00 - 13:20 Stéphanie Lheureux (Toronto): Introduction to Immune Modulation Therapy Focusing on PD1- anti PDL1 Checkpoint Inhibitors, CAR T-Cell Therapy and Vaccine Therapy
- 13:20 - 13:40 Christophe Le Tourneau (Paris): Unmet Challenges and Clinical Needs for Assessing Response to Immunotherapy
- 13:40 - 14:00 Lale Umutlu (Essen): Radiologic (CT) Aspects of Immune-Related Tumour Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Immunotherapy
- 14:00 - 14:15 Discussion
- 14:15 - 14:45 Coffee Break**
- 14:45 - 15:05 Egesta Lopci (Milan): FDG PET Imaging for Response to Immune Modulating Therapies
- 15:05 - 15:25 Rod Hicks (Melbourne): Case Series: How to Identify Pseudo Progression and Immune Toxicities on FDG PET
- 15:25 - 15:45 Elisabeth de Vries (Groningen): New Emerging PET Probes for Monitoring Immune Modulation Therapy
- 15:45 - 16:00 Panel Discussion

#### **Educational Objectives**

- to get familiar with the biological basis of the PD1-PDL1 immune checkpoint
- to learn about the expectations of the oncology community with regards to therapy assessment in patients undergoing immunotherapy
- to get familiar with the immune-related response criteria used in CT imaging (irRC)
- to learn about the ongoing evolutions of PET response criteria in the era of immunotherapy
- to learn about new PET probes for assessing immunotherapy

*Vienna, Austria*

Annual Congress of the  
European Association of Nuclear Medicine

October 21 –25, 2017  
Vienna, Austria

## **Summary**

The symposium will cover of the aspects of immunotherapy, from the biological basis of the PD1-PDL1 immune checkpoint to the development of new PET tracers for imaging of this tumour pathway. Experts in the field of Oncology will discuss the challenges they face when using immunotherapy, from difficulties to assess tumour response to immunotherapy-related side effects. A focus on therapy assessment with FDG PET will shed light on how the PET community can deal with the issue of pseudo progression and immune toxicities, including recent advances such as refinement of the Lugano Classification lymphoma response criteria, and a series of interactive clinical cases discussed by an expert in the field.